Compare Inovio Pharmaceuticals Inc (INO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Williams Companies Inc trades at $73.07 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 788.7× Inovio Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Williams Companies Inc for 58 Days on average.
| INO | WMB | |
|---|---|---|
Market Cap | $112.19M | $88.48B |
Volume | 3,201,278 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $2.65 | $79.40 |
52-Week Low | $0.66 | $56.51 |
Typical Hold Time | 43 Days | 58 Days |
Enterprise Value | $83.51M | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Williams Companies (WMB) trades at $72.68, up 1.71% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while Q2 narrowly missed. Technical indicators signal bullish momentum with support at $71-$72 and resistance at $73-$74. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.27 price target upside. Key risks include energy market volatility and high debt levels. The AI-driven data center growth provides tailwinds for natural gas demand, supporting long-term revenue stability. Investors should weigh the attractive dividend yield against exposure to commodity price fluctuations and capital expenditure requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
